The Hospital for Special Surgery (HSS) was recently given a $6.2 million grant from the Tow Foundation to help them apply genomics to expand research in autoimmune diseases, tissue repair and precision medicine.
The ultimate goal of this research is to increase patients’ mobility and decrease their pain levels by aiding doctors in choosing the best treatment options for them. The David Z. Rosensweig Genomics Research Center, which is where everything is being developed, will continue to look into diseases that cause massive pain and disability.
We are honored to receive this extraordinary grant from The Tow Foundation to build upon our unparalleled knowledge, and extensive data sets and patient populations to conduct transformational new research with high impact and potential for translation to improved patient care,” said Lionel B. Ivashkiv, MD, Chief Scientific Officer and Director of the Rosensweig Center. “The expanded Rosensweig Center will harness HSS’s unique strengths by bringing together world-class scientists in the typically distinct areas of immunology and musculoskeletal biology, and by leveraging our genomics expertise together with the expertise of our collaborators in data analytics, AI/machine learning, advanced genomics technologies, and stem cell biology.”
The next step for the Rosensweig Center following the grant is to boost precision medicine efforts by adopting “big data” approaches and exploring how the dysregulation of particular immune cells drives autoimmune diseases.
“Orthopedic and rheumatologic conditions are the world’s leading cause of disability worldwide, and HSS has a special responsibility and opportunity to relieve their burden on people, businesses, and society as a whole,” said Bryan T. Kelly, MD, MBA, HSS President and CEO and Surgeon-in-Chief Emeritus.